CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Directors as Chairman, effective immediately. Dr. Pomerantz is currently the President, Chief Executive Officer and Chairman of the Board of Directors of ContraFect.

REHOVOT, Israel , Sept. 26, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) , a regenerative medicine company, today announced financial results for the second quarter ended June 30, 2019 and provided an ...

CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the full year ended December 31, 2019 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See 'Use of Non-GAAP Measures' below.

CollPlant (NASDAQ:CLGN) , a regenerative and aesthetics medicine company, today announced that it will be hosting a webinar on Tuesday, May 12, 2020 at 11 am EDT/6 pm IDT that will feature its Co-Founder and Chief Scientist, Professor Oded Shoseyov and Chief Executive Officer, Mr. Yehiel Tal. The webinar will showcase the Company's journey to develop transformative patient solutions in regenerative and aesthetic medicine via its innovative plant-based, human recombinant collagen (rhCollagen) platform.

REHOVOT, Israel, Oct. 16, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced the Company's Chief Executive Officer Yehiel Tal will present at the Dawson James 5th Annual Small Cap Growth Conference on Tuesday, October 29, 2019 at 1:10 p.m. ET. Mr. Tal will provide an overview of the Company's business, including in the fields of medical aesthetics including breast implants, and 3D bioprinting of tissues and organs.

CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Top Ranked Momentum Stocks to Buy for October 11th

REHOVOT, Israel, Sept. 9, 2019 /PRNewswire/ -- CollPlant (CLGN) (the "Company"), a regenerative medicine company, announced it has closed on a total of $5.5 million in convertible loans. A group of U.S. accredited investors with deep experience in the 3D printing industry purchased $3.5 million of the convertible loans, and the Company's largest shareholder, Ami Sagi, purchased $2.0 million of the convertible loans, through a non-brokered private placement. An additional $1.0 million investment will be made by Ami Sagi following the execution of a license and/or a co-development agreement between CollPlant and a strategic business partner, if such were to occur.

CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See "Use of Non-GAAP Measures" below.

Is (CLGN) Outperforming Other Medical Stocks This Year?

CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced financial results for the third quarter ended September 30, 2019 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See "Use of Non-IFRS (non-GAAP) Measures" below.

CollPlant (NASDAQ: CLGN) (the "Company"), a regenerative and aesthetic medicine company, announced it has entered into definitive agreements for up to $4.45 million. The capital raise is by way of a non-brokered private placement with U.S. accredited investors who have many years of deep experience in medical and 3D printing.

CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced it is now part of a new public-private ManufacturingUSA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI brings together a consortium of over 150 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs.

REHOVOT, Israel, Sept. 3, 2019 /PRNewswire/ -- CollPlant (CLGN) (the "Company"), a regenerative medicine company, announced it has entered into definitive agreements for up to $6.5 million funding in convertible loans. The capital raise is by way of a non-brokered private placement with Ami Sagi, the Company's largest shareholder, and U.S. accredited investors with many years of deep experience in 3D printing. Under the terms of the transaction, the initial closing with Mr. Sagi occurred on September 3 2019 where Mr. Sagi funded the Company with $2.0 million.

REHOVOT, Israel, Oct. 22, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced the Company's Chief Executive Officer Yehiel Tal was recently appointed as a member of the Industry Relations Committee of ISBF (International Society for Biofabrication).

CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced the launch of its updated corporate website. The new website has a clean uncluttered design, improved functionality and enhanced rich content focused on the Company's growth into its core business segments: Medical Aesthetics and 3D Bioprinting of tissues and organs.

REHOVOT, Israel, Sept. 5, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced that  Yehiel Tal, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on Tuesday, September 10th, 2019 at 1:45 pm EDT. Mr. Tal will provide an overview of the Company's business, including in the fields of medical aesthetics, breast implants and 3D bioprinting of life saving organs. CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics.

3D Systems (DDD) and CollPlant aim to create state-of-the-art 3D bioprinters and BioInks to produce tissues and scaffolds.

CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that Yehiel Tal, Chief Executive Officer of CollPlant Biotechnologies, has issued a Letter to Shareholders, the full text of which follows below.

Today, 3D Systems (NYSE: DDD) and CollPlant Biotechnologies (NASDAQ: CLGN), announced signing a joint development agreement intended to play a pivotal role in advancing and accelerating breakthroughs in the biomedical industry. The collaboration brings together two industry pioneers--3D Systems, renowned for its 3D printing technologies and healthcare expertise; and CollPlant, the developer of proprietary recombinant human collagen (rhCollagen) BioInk technology currently used for 3D bioprinting of tissues and organs. The two companies plan to jointly develop tissue and scaffold bioprinting processes for third party collaborators.